<![CDATA[A drug nearing regulatory approval, daraxonrasib, is the first to substantially extend the lives of patients with pancreatic cancer.]]>A drug nearing regulatory approval, daraxonrasib, is the first to substantially extend the lives of patients with pancreatic cancer. It works by targeting a cellular protein that fuels not just nearly all pancreatic tumors, but also many lung and colon cancers. Those three are the leading causes of cancer deaths.

https://www.nytimes.com/2026/05/12/health/pancreatic-cancer-daraxonrasib-kras.html

]]>https://postcall.pub/topic/226dc6c6-6c73-40cb-9229-88ac633f6f2c/a-drug-nearing-regulatory-approval-daraxonrasib-is-the-first-to-substantially-extend-the-lives-of-patients-with-pancreatic-cancer.RSS for NodeMon, 25 May 2026 01:30:55 GMTTue, 12 May 2026 11:11:31 GMT60